Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment

Not yet recruiting

Phase 2 Results N/A

Summary of Purpose

The overarching objective of the Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART) trial is to assess whether a polypill containing fixed doses of (2/3) antihypertensives, a statin and antiplatelet therapy taken once daily orally would result in carotid intimal thickness regression-a surrogate marker of atherosclerosis, improved adherence, and tolerability compared...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 30 October 2017.

1 Jan 2018 28 Aug 2017 1 Aug 2018 1 Aug 2019 1 Oct 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available

Contacts